Pharmaceutical research and development: what do we get for all that money?

Abstract

Data indicate that the widely touted “innovation crisis” in pharmaceuticals is a myth. The real innovation crisis, say <b>Donald Light</b> and <b>Joel Lexchin</b>, stems from current incentives that reward companies for developing large numbers of new drugs with few clinical advantages over existing ones